Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Julian who wrote (750)	11/18/1999 12:59:00 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

Julian, 1. Thanks for not shouting. I'm very happy to see that you discovered the CAPS LOCK key. I was beginning to wonder if you just deliberately chose to be rude. <g> 2. Is Christine Charette the Nesbitt Burns Analyst? 3. DYNAMITE RECOMMENDATION!!! RECOMMENDATION: We are upgrading the stock from an S4 to an S5. The average price increase for "single" large product companies between advisory committee meeting and approval is about 50% with a range of -10% to 150%. We believe QLT should perform above average given the concerns regarding potential for approval that have circulated in the past few weeks. This sounds very much like close to zero probability of any downside from the $38US Tuesday close. 50% takes us to $57US. 150% takes us to $95US. A target price of about $100 to $150 Cdn sounds very very good to me. :-) Thanks for the report. Ian.